Coagulation Test Interpretation

Normal Reference Ranges

• The normal reference range for bleeding time is 2-9 minutes, for prothrombin time (PT) is 11-13.5 seconds or PT ratio <1.4, and for activated partial thromboplastin time (aPTT) is 25-35 seconds or aPTT ratio <1.4, as recommended by the American Thoracic Society 1
• Traditional bleeding time test has largely been replaced by more standardized coagulation assays, but normal range is typically 2-9 minutes 1
• Normal PT range is 11-13.5 seconds, which varies slightly by laboratory, according to the American College of Critical Care Medicine 2
• Normal aPTT range is 25-35 seconds, which varies slightly by laboratory, as stated by the American College of Critical Care Medicine and the American Society of Anesthesiologists 2, 3

Clinical Significance of These Tests

• PT measures the extrinsic and common pathways of coagulation, and is prolonged in liver disease, as noted by the American Thoracic Society 1
• PT is also prolonged in disseminated intravascular coagulation (DIC), according to the American College of Cardiology 4
• aPTT measures the intrinsic and common pathways of coagulation, and is prolonged in hemophilia A and B, as stated by the American College of Cardiology 4
• aPTT is also prolonged in von Willebrand disease, presence of lupus anticoagulant, and heparin therapy, as noted by the American College of Cardiology and the American Society of Anesthesiologists 3, 4, 5
• For patients on warfarin therapy, target INR is typically 2.0-3.0 for most indications, as recommended by the International Society on Thrombosis and Haemostasis 5

Important Considerations

• For patients requiring invasive procedures, a PT ratio or aPTT ratio >1.4 is generally considered a relative contraindication, as stated by the American Thoracic Society 1
• For patients with bleeding, a normal thrombin time (TT) excludes clinically relevant dabigatran levels, while a prolonged aPTT suggests the presence of therapeutic or above therapeutic levels, according to the American Society of Anesthesiologists and the American College of Cardiology 3, 4
• Platelet count should also be evaluated alongside PT and aPTT, with counts <100,000/ml considered a relative contraindication to invasive procedures, as noted by the American Thoracic Society 1
• Normal PT/aPTT values don't exclude all bleeding disorders, particularly those affecting platelet function, as stated by the American College of Critical Care Medicine 2

Clinical Significance and Interpretation of PT/INR and APTT Values

Normal Reference Ranges and Clinical Significance

• The International Society on Thrombosis and Haemostasis recommends that INR was specifically designed and validated to standardize PT results for monitoring vitamin K antagonist therapy, not as a general predictor of bleeding risk in other contexts 6
• For patients on warfarin therapy, the American College of Cardiology recommends a therapeutic INR range of 2.0-3.0 for most indications, with a moderate strength of evidence 7

Interpretation in Different Clinical Contexts

• The British Thoracic Society recommends that for patients not on anticoagulation therapy, a PT ratio or APTT ratio >1.4 times the normal control is generally considered abnormal, based on low-quality evidence 8
• The International Society on Thrombosis and Haemostasis recommends that for patients on vitamin K antagonist therapy, INR values between 2.0-3.0 are typically targeted for most indications, with a high strength of evidence 7, 9

Coagulation Parameters for Invasive Procedures

Access Site Considerations

• For transfemoral procedures, stricter coagulation parameters may be needed compared to transradial access, according to the American College of Cardiology 10
• When using transradial access, coagulation parameters can be slightly more lenient due to lower bleeding risk, as recommended by the American College of Cardiology 10

Special Considerations

• For patients on anticoagulation therapy requiring procedures, the American College of Cardiology recommends deferring procedure until INR is ≤2.0 for patients on warfarin 10
• For patients on DOACs, the American College of Cardiology suggests that timing depends on the specific agent, renal function, and access site (transradial vs. transfemoral) 10

Concerning PT, PTT, and INR Level Thresholds for Patients on Warfarin Therapy

Target INR Ranges for Specific Clinical Indications

• The American Geriatrics Society recommends target INR ranges of 2.0-3.0 for most indications, such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE), and 2.5-3.5 for mechanical prosthetic heart valves and acute myocardial infarction with high embolic risk 11
• For patients on warfarin therapy, an INR <2.0 is considered subtherapeutic, increasing the risk of thrombosis, while an INR >3.0 increases the risk of bleeding 11
• An INR >5.0 without bleeding requires dose adjustment and close monitoring, and an INR >9.0 poses a high risk of serious bleeding, necessitating immediate intervention 11

Management of Elevated INR Values

• For INR values between 5.0-9.0 without bleeding, withholding warfarin and considering oral vitamin K (1.0-2.5 mg) is recommended, and for rapid INR reversal, vitamin K (2.0-4.0 mg) can be given orally 11

Baseline INR of 1.4: Clinical Significance and Guidelines

Normal Reference Range and Clinical Interpretation

• An INR of 1.4 represents only a minimal elevation above the upper limit of normal and falls within the range that many laboratories consider acceptable variation, according to the American College of Chest Physicians 12
• The American College of Chest Physicians pediatric anticoagulation guidelines define baseline INR of 1.0-1.3 as normal for initiating warfarin therapy, and an INR of 1.1-1.4 prompts a 20% dose increase during maintenance therapy, indicating this range is considered subtherapeutic but not dangerous 12

Clinical Interpretation in Specific Contexts

• A retrospective cohort study of 233 patients with nonvariceal upper GI bleeding found that baseline INR <1.3 versus ≥1.3 did not predict rebleeding, transfusion requirement, surgery, length of stay, or mortality, and endoscopic treatment with injection or heater probe may be safely performed in patients with INR <2.5, as reported in the Annals of Internal Medicine 13
• In the RUGBE Canadian cohort study of 1,869 patients, neither INR nor platelet count predicted rebleeding, though presentation INR ≥1.5 was a significant predictor of mortality, likely reflecting comorbidity burden rather than coagulopathy itself, according to the Annals of Internal Medicine 13

Limitations of INR in Predicting Bleeding Risk

• In patients not on warfarin, INR has limited predictive value for bleeding complications, as stated in the Journal of Thrombosis and Haemostasis 14
• An INR of 1.4 does not represent clinically significant coagulopathy requiring intervention, and does not predict adverse outcomes in patients with upper GI bleeding, according to the Annals of Internal Medicine 13

Guidance on Coagulation Testing Prior to Laparoscopic Cholecystectomy

Recommendations on Additional Laboratory Evaluation

• In patients scheduled for laparoscopic cholecystectomy who have normal PT, INR, and PTT results, the American Society of Anesthesiologists advises that further coagulation studies (e.g., repeat PT/INR/PTT, factor assays) are unnecessary, as they do not improve peri‑operative safety and may cause avoidable delays in surgery. 15

Criteria for Proceeding with Surgery

• When standard coagulation screens (PT, INR, PTT) are within normal limits and there is no personal or family history of bleeding disorders, the ASA states that these results are sufficient to proceed with laparoscopic cholecystectomy without additional hemostatic testing. 15